Susanne Ackermann

Susanne Ackermann

Auto-generated profile, based on publicly available information

Susanne Ackermann

Klinik für Innere Medizin III, AG Experimentelle Nephrologie, Universitätsklinikum Jena, Jena, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CYChangjun Yin
Changjun Yin
SASusanne Ackermann
Susanne Ackermann
ZMZhe Ma
Zhe Ma
SMSarajo Mohanta
Sarajo Mohanta
CZChuankai Zhang
Chuankai Zhang
AHAndreas JR Habenicht
Andreas JR Habenicht

5 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DPDiana Pauly
Diana Pauly
BNBenedikt M. Nagel
Benedikt M. Nagel
JRJörg Reinders
Jörg Reinders
TKTobias Killian
Tobias Killian
MWMatthias Wulf
Matthias Wulf
Bernhard WeberBernhard Weber
Bernhard Weber
The complement system is an essential part of the innate immune system by acting as a first line of defense which is stabilized by properdin, the sole known positive regulator of the alternative complement pathway. Dysregulation of complement can promote a diversity of human inflammatory diseases which are treated by complement inhibitors. Here, we generated a novel blocking monoclonal antibody (mAb) against properdin and devised a new diagnostic assay for this important complement regulator. Mouse mAb 1340 specifically detected native properdin from human samples with high avidity. MAb 1340 inhibited specifically the alternative complement mediated cell lysis within a concentration range of 1–10 µg/mL. Thus, in vitro anti-properdin mAb 1340 was up to fifteen times more efficient in blocking the complement system as compared to anti-C5 or anti-Ba antibodies. Computer-assisted modelling suggested a three-dimensional binding epitope in a properdin-C3(H2O)-clusterin complex to be responsible for the inhibition. Recovery of properdin in a newly established sandwich ELISA using mAb 1340 was determined at 80–125% for blood sample dilutions above 1∶50. Reproducibility assays showed a variation below 25% at dilutions less than 1∶1,000. Systemic properdin concentrations of healthy controls and patients with age-related macular degeneration or rheumatic diseases were all in the range of 13–30 µg/mL and did not reveal significant differences. These initial results encourage further investigation into the functional role of properdin in the development, progression and treatment of diseases related to the alternative complement pathway. Thus, mAb 1340 represents a potent properdin inhibitor suitable for further research to understand the exact mechanisms how properdin activates the complement C3-convertase and to determine quantitative levels of properdin in biological samples.

14 March 2019 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
SASusanne Ackermann
Susanne Ackermann
RMRalf Mrowka
Ralf Mrowka

4 February 2019 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CYChangjun Yin
Changjun Yin
SASusanne Ackermann
Susanne Ackermann
ZMZhe Ma
Zhe Ma
SMSarajo Mohanta
Sarajo Mohanta
CZChuankai Zhang
Chuankai Zhang
AHAndreas JR Habenicht
Andreas JR Habenicht
In the version of this article originally published, a sentence was erroneously included in the author contributions, and information regarding second shared authorship was missing from the author contributions. The following should not have been included in the author contributions: “C.W. and A.J.R.H. supervised the work presented in Figs. 1, 2, 5, 6; P.Z. and C.S. supervised the work presented in Figs. 3, 4.” Additionally, this sentence should have appeared at the beginning of the author contributions: “These authors contributed equally: C.W., P.F.Z., C.S., and A.J.R.H.” The errors have been corrected in the print, PDF and HTML versions of the article.

8 July 2018 in Acta Physiologica
Verified
Journal Article
Open access
PDF file
SASusanne Ackermann
Susanne Ackermann
RMRalf Mrowka
Ralf Mrowka
Nephropathy denotes a loss of kidney function due to renal disease or kidney damage. In general this can be caused by inflammation or non‐inflammatory causes. Non‐inflammatory processes leading to nephropathy are for example a decreased glomerular flow rate (GFR), exposure to renal toxins (e. g. drugs) and renal trauma. Acute kidney injuries (AKI) occur global and are a common challenge in hospitals.